Тестостерон и рак предстательной железы: правда и вымысел о простатической безопасности андрогенотерапии

1. Гормонотерапия. Под ред. Х.Шамбаха, Г.Кнаппе, В.Карола. Пер. с нем. М.: Медицина, 1988.
2. Дильман В.М. Эндокринологическая онкология. М.: Медицина, 1983.
3. Коган М.И., Савзиханов Р.Т. Влияние андрогензаместительной терапии на симптомы нижних мочевых путей. Материалы Международного конгресса по андрологии. Сочи, Дагомыс, 2009; с. 133–4.
4. Переверзев А.С., Сергиенко Н.Ф., Илюхин Ю.А. Заболевания предстательной железы. Харьков, 2005.
5. Adler HL, McCurdy MA, Kattan MW et al. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999; 161: 182–7.
6. Albanes D, Weinstein SJ, Wright ME et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. J Natl Cancer Inst 2009; 101: 1272–9.
7. Bruchovsky N, Wilson JD. The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro. J Biol Chem 1968; 243 (8): 2012–21.
8. Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563–6.
9. Chan JM, Stampfer MJ, Ma J et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099–106.
10. Colao A, Di Somma C, Cascella T et al. Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol 2008; 159: 389–97.
11. Coman I, Cri-an N, Marian A et al. Prevalence of the metabolic syndrome in patients with prostate cancer. J Gastrointestin Liver Dis 2008; 17: 237–8.
12. De Santana IA, Moura GS, Vieira NF, Cipolotti R. Metabolic syndrome in patients with prostate cancer. Sao Paulo Med J 2008; 126: 274–8.
13. Efstratiadis G, Tsiaousis G, Athyros VG et al. Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. Angiology 2006; 57: 303–11.
14. Engeland A, Tretli S, Bjorge T. Height, body mass index, and prostate cancer: a follow-up of 950000 Norwegian men. Br J Cancer 2003; 89: 1237–42.
15. English KM, Steeds RP, Jones TH et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation 2000; 102 (16): 1906–11.
16. Garay-Sevilla ME, Nava LE, Malacara JM et al. Advanced glycosylation end products (AGEs), insulin- like growth factor-1 (IGF-1) and IGF-binding protein-3 (IGFBP-3) in patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2000; 16: 106–13.
17. Gorbachinsky I et al. Metabolic Syndrome and Urological Deseases. Rev Urol 2010; 12 (4): 157–80.
18. Hammarsten J, Högstedt B. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 2004; 13: 47–55.
19. Hammarsten J, Högstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer 2005; 41: 2887–95.
20. Han JH, Choi NY, Bang SH et al. Relationship between serum prostate-specific antigen levels and components of metabolic syndrome in healthy men. Urology 2008; 72: 749–54.
21. Hsieh CC, Thanos A, Mitropoulos D et al. Risk factors for prostate cancer: a case-control study in Greece. Int J Cancer 1999; 80: 699–703.
22. Hsing AW, Sakoda LC, Chua S. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr 2007; 86: 843–57.
23. Huggins С, Stevens RE, Hodges CV. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941; 43: 209–23.
24. Il’yasova D, Colbert LH, Harris TB et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 2413–18.
25. Isom-Batz G, Bianco FJ, Kattan MW et al. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005; 173: 1935–7.
26. ISSAM: Late-on set Hypogonadism Recommendations, 2008.
27. Jayachandran J, Bañez LL, Aronson WJ et al. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2009; 115: 5263–71.
28. Kalinchenko SY, Tishova YA, Mskhalaya GJ et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010; 73 (5): 602–12.
29. Kasper JS, Liu Y, Giovannucci E. Diabetes mellitus and risk of prostate cancer in the health professionals follow-up study. Int J Cancer 2009; 124: 1398–403.
30. Kooijman R, Himpe E, Potikanond S, Coppens A. Regulation of interleukin-8 expression in human prostate cancer cells by insulin-like growth factor-I and inflammatory cytokines. Growth Horm IGF Res 2007; 17: 383–91.
31. Kurahashi N, Iwasaki M, Sasazuki S et al. Association of body mass index and height with risk of prostate cancer among middle-aged Japanese men. Br J Cancer 2006; 94: 740–2.
32. Laukkanen JA, Laukkanen JA, Niskanen L et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol. Biomarkers Prev 2004; 13: 1646–50.
33. Lee LF, Louie MC, Desai SJ et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 2004; 23: 2197–205.
34. Lehrer S, Diamond EJ, Mamkine B et al. Serum interleukin-8 is elevated in men with prostate cancer and bone metastases. Technol. Cancer Treat Res 2004; 3: 411.
35. Lessard L, Karakiewicz PI, Bellon-Gagnon P et al. Nuclear localization of nuclear factor-kappaB p65 in primary prostate tumors is highly predictive of pelvic lymph node metastases. Clin Cancer Res 2006; 12: 5741–5.
36. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control 2006; 17: 989–1003.
37. Martin RM, Vatten L, Gunnell D et al. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway. Cancer Causes Control 2009; 20: 1181–92.
38. Massengil J et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169 (5): 1670–5.
39. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004; 90: 2312–16.
40. Mizokami A, Gotoh A, Yamada H et al. Tumor necrosis factor-alpha represses androgen sensitivity in the LNCaP prostate cancer cell line. J Urol 2000; 164 (3 Pt 1): 800–5.
41. Moore SC, Leitzmann MF, Albanes D et al. Adipokine genes and prostate cancer risk. Int J Cancer 2009; 124: 869–76.
42. Morote J, Ramirez C, Gómez E et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int 2009; 104: 486–9.
43. Nazem B, Saad A, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009; 5: 427–48.
44. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997; 57: 141–6.
45. Palayoor ST, Youmell MY, Calderwood SK et al. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999; 18: 7389–94.
46. Pflug BR, Pecher SM, Brink AW et al. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model. Prostate 2003; 57: 245–54.
47. Platz EA, Leitzmann MF, Rifai N et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev 2005; 14: 1262–9.
48. Renehan AG, Zwahlen M, Minder C et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346–53.
49. Roddam AW, Allen NE, Appleby P et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 2008; 149: 461–71.
50. Rodriguez C, Patel AV, Mondul AM et al. Diabetes and risk of prostate cancer in a prospective cohort of US men. Am J Epidemiol 2005; 161: 147–52.
51. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 2002; 63: 1921–35.
52. Schatzl G, Madersbacher S, Haitel A et al. Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. J Urol 2003; 169: 1312–5.
53. Sierra-Johnson J, Romero-Corral A, Somers VK et al. IGF-I/IGFBP-3 ratio: a mechanistic insight into the metabolic syndrome. Clin Sci (Lond) 2009; 116: 507–12.
54. Stearns M, Tran J, Francis MK et al. Activated Ras enhances insulin-like growth factor I induction of vascular endothelial growth factor in prostate epithelial cells. Cancer Res 2005; 65: 2085–8.
55. Stewart RJ, Panigraphy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001; 165: 688–93.
56. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J Cell Biochem 2004; 91: 100–17.
57. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006; 164: 1094–102.
58. Tavani A, Gallus S, Bertuzzi M et al. Diabetes mellitus and the risk of prostate cancer in Italy. Eur Urol 2005; 47: 313–7.
59. Teloken C, da Ros CT, Caraver F et al. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. J Urol 2005; 174: 2178–80.
60. Tomlinson JW, Finney J, Hughes BA et al. Reduced glucocorticoid production rate, decreased 5alpha-reductase activity, and adipose tissue insulin sensitization after weight loss. Diabetes 2008; 57: 1536–43.
61. Traish AM, Saad F, Guay A. The dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistance. J Androl 2009; 30: 23–32.
62. Tuohimaa P, Tenkanen L, Syvälä H et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2007;16: 302–7.
63. Ulmer H, Borena W, Rapp K et al. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 2009; 101: 1202–6.
64. Vale S. Increased activity of the oncogenic fatty acid synthase and the impaired glucose uptake in the metabolic syndrome. Cancer Epidemiol Biomarkers Prev 2009; 18: 2151.
65. Vykhovanets EV, Shukla S, MacLennan GT et al. Molecular imaging of NF-kappaB in prostate tissue after systemic administration of IL-1 beta. Prostate 2008; 68: 34–41.

1С.Ю.Калинченко, 2И.А.Тюзиков, 1Ю.А.Тишова, 3Е.А.Греков 

1. Кафедра эндокринологии ФПКМР ГБОУ ВПО РУДН, Москва; 
2. Медицинский Центр диагностики и профилактики-Плюс, Ярославль; 
3. ФГБУ НИИ урологии Минздрава РФ, Москва